| Francesca Nicole Porter, LADC I | |
|
39 Burnham St, Enfield, CT 06082-6144 | |
| (774) 571-5193 | |
| Not Available |
| Full Name | Francesca Nicole Porter |
|---|---|
| Gender | Female |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | 39 Burnham St, Enfield, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003428897 | NPI | - | NPPES |
| 16680 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 16680 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Francesca Nicole Porter, LADC I 39 Burnham St, Enfield, CT 06082-6144 Ph: (774) 571-5193 | Francesca Nicole Porter, LADC I 39 Burnham St, Enfield, CT 06082-6144 Ph: (774) 571-5193 |
News Archive
A new strategy for fighting cancer aims to make its genes get lost in translation, according to a report in the January 26, 2007, issue of the journal Cell.
Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.
Measuring a set of protein changes in the blood linked to alcohol use may potentially lead to a more accurate diagnostic test than those currently available, according to Penn State College of Medicine researchers.
ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.
libragen, a contract research organization dedicated to biocatalysis and metagenomics, has been a major contributor to the success of PolyModE (Polysaccharide Modifying Enzymes), a large collaborative research project funded by the European Community. The project, which began in 2009 and ended in April this year, looked at developing novel polysaccharide modifying enzymes for the optimized use of hydrocolloids as, for example, food additives or novel therapeutic agents in the food sciences and medical industries. Researchers focused on six industry-targeted hydrocolloids (alginates, carrageenans, chitosans, glycosaminoglycans, pectins, and xanthan gums) where traditional chemistry fails to achieve a certain desired modification.
› Verified 9 days ago
Shaliar Drew, Counselor Medicare: Not Enrolled in Medicare Practice Location: 153 Hazard Ave, Enfield, CT 06082 Phone: 860-253-5020 Fax: 860-253-5030 | |
Meiline Smith, Counselor Medicare: Not Enrolled in Medicare Practice Location: 153 Hazard Ave, Enfield, CT 06082 Phone: 860-253-5020 Fax: 860-253-5030 | |
Francis May, Counselor Medicare: Not Enrolled in Medicare Practice Location: 113 Elm St, Suite 204, Enfield, CT 06082 Phone: 860-741-3001 Fax: 860-741-8332 | |
Monica E Crimmins, Counselor Medicare: Not Enrolled in Medicare Practice Location: 153 Hazard Ave, Enfield, CT 06082 Phone: 877-884-3571 Fax: 860-731-5536 | |
Heidi Schuman, Counselor Medicare: Not Enrolled in Medicare Practice Location: 707 Barbara Jean Dr, Enfield, CT 06082 Phone: 518-424-6719 | |
Melissa Reale, Counselor Medicare: Not Enrolled in Medicare Practice Location: 47 Palomba Dr, Enfield, CT 06082 Phone: 860-253-5020 Fax: 860-253-5030 |